An announcement from Virpax Pharmaceuticals (VRPX) is now available.
Virpax Pharmaceuticals has parted ways with Dr. Jeffrey Gudin, who resigned from his roles as Chief Medical Officer and Executive Vice President, though he’ll stay on as a Class III Director. His departure is amicable, without any disputes over the company’s operation or policies. Dr. Gudin will receive a severance of $81,900 paid over six months and will maintain his health benefits for up to six months or until he finds new employment. His stock options remain in effect, allowing him to purchase shares according to the existing incentive plan. The separation agreement also includes a mutual non-disparagement clause to maintain professional respect post-departure.
See more data about VRPX stock on TipRanks’ Stock Analysis page.
